Oncotarget

Research Papers:

Prognostic factors for histiocytic and dendritic cell neoplasms

Joji Shimono, Hiroaki Miyoshi _, Fumiko Arakawa, Kensaku Sato, Takuya Furuta, Reiji Muto, Eriko Yanagida, Yuya Sasaki, Daisuke Kurita, Keisuke Kawamoto, Koji Nagafuji and Koichi Ohshima

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:98723-98732. https://doi.org/10.18632/oncotarget.21920

Metrics: PDF 1718 views  |   HTML 2840 views  |   ?  


Abstract

Joji Shimono1,3, Hiroaki Miyoshi1, Fumiko Arakawa1, Kensaku Sato1, Takuya Furuta1, Reiji Muto1, Eriko Yanagida1, Yuya Sasaki1, Daisuke Kurita1, Keisuke Kawamoto1, Koji Nagafuji2 and Koichi Ohshima1

1Department of Pathology, Kurume University, School of Medicine, Kurume, Japan

2Department of Hematology, Kurume University, School of Medicine, Kurume, Japan

3Department of Hematology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Correspondence to:

Hiroaki Miyoshi, email: [email protected]

Keywords: dendritic cell neoplasm; histiocytic sarcoma; survival; prognostic factor; BRAF

Received: June 05, 2017    Accepted: September 21, 2017    Published: October 19, 2017

ABSTRACT

Histiocytic and dendritic cell neoplasms are rare and poorly studied. We report the clinical characteristics and prognostic factors in such cases in Japan. We investigated the clinical characteristics and survival in 87 adult patients with histiocytic and dendritic cell neoplasms. Fifty patients had histiocytic sarcoma, 12 had Langerhans cell histiocytosis, 11 had follicular dendritic cell sarcoma, 8 had Langerhans cell sarcoma, 6 had interdigitating cell sarcoma and 1 had indeterminate dendritic cell sarcoma. The median follow-up period was 18.0 (range: 9.6-71.8) months, and median overall survival (OS) was 23.5 months. The 2-year OS rate was 49.2%. In the multivariate analysis, elevated lactate dehydrogenase (LDH) (p =.004), ECOG performance status (PS) 2-4 (p =.006), and Ann Arbor stage III-IV (p =.008) affected OS. Stratification by elevated LDH, ECOG PS 2-4, and Ann Arbor stage III-IV allowed classification of patients into low risk, intermediate risk, and high risk groups. The same classification was applicable for HS and non-HS categories. In the rare neoplasms of histiocytic and dendritic cell sarcoma, ECOG PS, Ann Arbor stage, and LDH are important prognostic factors for predicting survival.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21920